Hemaquest is the company set up to bring the drug known as HQK-1001 to market. HQK-1001 is a fetal hemoglobin inducing drug that is currently in stage two trials. The hopes are that it can raise Hb level by as much as 3-4 points, which would eliminate the need for transfusion in most thal intermedias, and hopefully will reduce the amount of blood majors need. The drug was developed by Dr Susan Perrine. It is not related to gene therapy.